JuliaFurtner,
VeronikaSch?pf,
KatharinaSeystahl,
EmilieLeRhun,
CorrespondingAuthor:MatthiasPreusser,MD,DepartmentofMedicineI,ComprehensiveCancerCenter,CNSUnit(CCC-CNS),MedicalUniversityofVienna,W?hringerGürtel18-20,Vienna,Austria(matthias.preusser
meduniwien.ac.at).AbstractBackgroundTheefficacyofsystemicantineoplastictherapyonrecurrentWorldHealthOrganization(WHO)gradesIIandIIImeningiomasisunclear.
MethodsWeperformedaretrospectivemulticenteranalysisofserialcranialMRIinpatientswithrecurrentWHOIIandIIImeningiomastreatedwithantineoplasticsystemictherapies.Growthratesfortumorvolumeanddiameter,aswellaschangeratesforedemasize,werecalculatedforalllesions.
ResultsWeidentifiedatotalof34patients(23atypical,11anaplasticmeningiomas)withatotalof57meningiomalesionswhohadbeentreatedat6Europeaninstitutions.Systemictherapiesincludedbevacizumab,cytotoxicchemotherapy,somatostatinanalogues,andtyrosinekinaseinhibitors.Overall,tumorgrowthratesdecreasedduringsystemictherapyby51%fortumordiameterand14%fortumorvolumegrowthrates中药治疗白癜风白癜风的专科专家
转载请注明：http://www.tzdgt.com/dynmldynml/3045.html
